Gilead rep minimised Letairis's risk plan, US FDA says
This article was originally published in Scrip
A Gilead Sciences
You may also be interested in...
A former senior leader in Johnson & Johnson’s medical devices business will take over the reins of the Biotechnology Innovation Organization from Jim Greenwood in June. McMurry-Heath – who also spent four years at the US FDA's device center as associate director of science – brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.
Recent panel review of biologics center's intramural research programs had its share of technical glitches and involved agency speakers blindly presenting to committee members they could not see; the experience suggests the difficulties an industry sponsor with an application hanging in the balance may face if a virtual advisory committee were to be held.
Use of alternative labs or imaging centers depends upon type of assessment and reason it is being performed, the US agency's revised guidance states; missed milestones for postmarketing studies required under accelerated approval will need to be justified.